PCN97 Cost-Effectiveness of Atezolizumab Monotherapy Versus Pembrolizumab Monotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.189
https://www.valueinhealthjournal.com/article/S1098-3015(21)00406-X/fulltext
Title :
PCN97 Cost-Effectiveness of Atezolizumab Monotherapy Versus Pembrolizumab Monotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00406-X&doi=10.1016/j.jval.2021.04.189
First page :
Section Title :
Open access? :
No
Section Order :
10766